Shifting the Paradigm: Bruton's Tyrosine Kinase (BTK) Inhibition as a Game Changer in Blood Cancer Therapy

The pathophysiology of BTK in haematological malignancies is characterised by its central role in aberrant BCR signalling that drives malignant B-cell survival, proliferation, and resistance. The discovery and development of BTK inhibitors have revolutionised the therapeutic approach to these diseases by specifically targeting this key molecular node, disrupting the pathological signalling cascades that sustain malignancy. BTK inhibitors can be broadly categorised into covalent and reversible types based on their mode of binding. Covalent inhibitors, such as ibrutinib, form an irreversible bond with the cysteine residue (C481) in the BTK active site. This permanent attachment prevents ATP binding and subsequent kinase activity, leading to durable inhibition of BCR signalling. The clinical success of BTK inhibitors has revolutionised the treatment of haematological malignancies, yet challenges remain that drive ongoing research and innovation. One significant future direction involves the development of next-generation BTK inhibitors designed to overcome resistance and improve safety profiles. Combination therapies have emerged as a crucial strategy to enhance the effectiveness of BTK inhibitors and to overcome mechanisms of resistance. One of the most promising combinations involves pairing BTK inhibitors with BCL-2 inhibitors such as venetoclax.